首页> 外文期刊>American Journal of Clinical and Experimental Medicine >Tacrolimus in the management of large facial patch with recurring reversal reaction: Outcome of a pilot clinical trial study on 5 patients
【24h】

Tacrolimus in the management of large facial patch with recurring reversal reaction: Outcome of a pilot clinical trial study on 5 patients

机译:他克莫司在治疗大型面部贴剂中具有反复逆转反应:一项针对5例患者的临床试验研究的结果

获取原文
           

摘要

Background: Inflamed large facial patch, being compromising the appearance and beauty of a patient, is a source of embarrassment and distress, and affects anti-leprosy drive adversely in many ways in the field situation. Its management with oral prednisolone alone, the mainstay of treatment for reversal reaction, proved disappointing. Objective: To see whether topical tacrolimus will be helpful in managing those patients. Methodology: We treated five adult patients with recurring reversal reaction in large facial patch with tacrolimus 0.1% ointment, twice daily and lower dose oral prednisolone for twelve months during March, 2012-February, 2013. Result: Complete remission was achieved in all cases. No side effects of whatsoever was seen in any patient. No recurrence of reaction is seen in any patient till to date. Conclusion: Tacrolimus ointment and lower dose prednisolone was found helpful in managing patients with recurring reversal reaction in large facial patch.
机译:背景:发红的大面部贴片损害了患者的外观和美感,是尴尬和困扰的根源,并且在现场情况下会以多种方式不利于麻风病的预防。令人失望的是,仅使用口服泼尼松龙作为逆转反应的治疗手段,其治疗令人失望。目的:观察局部他克莫司是否有助于治疗这些患者。方法:2012年3月至2013年2月,我们对5名成年患者进行了大面积面部复发逆转反应治疗,使用他克莫司0.1%软膏,每日两次和小剂量口服泼尼松龙口服治疗,为期12个月。结果:所有病例均获得完全缓解。在任何患者中均未见任何副作用。迄今为止,在任何患者中均未见反应复发。结论:他克莫司软膏和低剂量泼尼松龙被发现有助于治疗大面积面部复发逆转患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号